Is there a role for GLP-1 in the prevention and treatment of cancer?
Interest is growing rapidly in the field of oncology in the anti-obesity drug target that has recently been investigated in large retrospective studies and preclinical models
Analysis identifies proteins VISTA and VEGF-A as prognostic of poor survival in recurrent ovarian cancer
High expression of specific immune-oncology proteins may have utility in identifying high-risk patients to inform future trial design
Is targeted therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer on the horizon?
In the CAPItello281 trial, survival results with capivasertib plus abiraterone are promising, but questions remain on the accurate determination of PTEN loss in patients
Mixed results with enzalutamide in non-metastatic prostate cancer
Enzalutamide failed to deliver in high-risk localised prostate cancer, but improved survival, in combination with leuprolide, in biochemically recurrent prostate cancer
Harnessing Large Language Models in oncology: ESMO’s framework for integration in the clinic
The ELCAP statements, developed by a group of international experts, help oncology stakeholders recognise the opportunities and the risks of these artificial intelligence systems by categorising them into three types
Survival benefits demonstrated with immunochemotherapy in platinum-resistant ovarian cancer
The ENGOT-ov65/KEYNOTE-B96 trial reported small but clinically relevant progression-free survival increments and significantly improved overall survival in platinum-resistant ovarian cancer
Preventing cancer recurrence with novel antibody–drug conjugates
Presidential presentations in early breast cancer provide first evidence of ADCs rapidly moving into the curative setting across multiple cancer types
Peri-operative enfortumab vedotin plus pembrolizumab prolongs survival in muscle-invasive bladder cancer
In KEYNOTE-905/EV-303, the combination of an antibody–drug conjugate and immunotherapy showed statistically significant and clinically meaningful improvements in event-free survival and overall survival
Trastuzumab deruxtecan is moving to the curative setting in early HER2-positive breast cancer
Positive findings from the DESTINY-Breast05 and DESTINY-Breast11 trials suggest that a paradigm change in the treatment of high-risk patients may be imminent
Head and neck cancers: should research continue to invest in immunotherapy?
Despite growing disappointing results from clinical trials, focus should now turn to the design of studies to better reflect tumour heterogeneity